ME vs. ORGO, AURA, KALV, ETON, PRME, VALN, KRRO, ENGN, GLUE, and RGNX
Should you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Organogenesis (ORGO), Aura Biosciences (AURA), KalVista Pharmaceuticals (KALV), Eton Pharmaceuticals (ETON), Prime Medicine (PRME), Valneva (VALN), Korro Bio (KRRO), enGene (ENGN), Monte Rosa Therapeutics (GLUE), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry.
23andMe vs.
Organogenesis (NASDAQ:ORGO) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.
Organogenesis has higher revenue and earnings than 23andMe. Organogenesis is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.
Organogenesis has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.
Organogenesis received 85 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 66.44% of users gave Organogenesis an outperform vote while only 54.55% of users gave 23andMe an outperform vote.
Organogenesis currently has a consensus target price of $5.00, suggesting a potential upside of 47.71%. 23andMe has a consensus target price of $9.40, suggesting a potential upside of 162.20%. Given 23andMe's higher possible upside, analysts clearly believe 23andMe is more favorable than Organogenesis.
In the previous week, 23andMe had 5 more articles in the media than Organogenesis. MarketBeat recorded 7 mentions for 23andMe and 2 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.33 beat 23andMe's score of 0.19 indicating that Organogenesis is being referred to more favorably in the media.
49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 36.1% of 23andMe shares are owned by institutional investors. 36.9% of Organogenesis shares are owned by company insiders. Comparatively, 26.3% of 23andMe shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Organogenesis has a net margin of -1.62% compared to 23andMe's net margin of -318.39%. Organogenesis' return on equity of -2.69% beat 23andMe's return on equity.
Summary
Organogenesis beats 23andMe on 15 of the 18 factors compared between the two stocks.
Get 23andMe News Delivered to You Automatically
Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:ME) was last updated on 1/21/2025 by MarketBeat.com Staff
